Environmental Assessment for Pharmaceuticals

Charles Eirkson
Center for Veterinary Medicine
Keith Webber, Ph.D.
Center for Drug Evaluation and Research
Suzanne Fitzpatrick, Ph.D.
Office of the Commissioner

U.S. EPA
Las Vegas, NV
August 23-25, 2005
Agency’s Roles and Priorities

Primary Federal agency for regulating pharmaceuticals and personal care products.

- Foods
- **Human Drugs**
- **Animal Drugs**
- Cosmetics
- Medical Devices
Statutes & Regulations

Statutory authorities:
- Food, Drug, & Cosmetic Act of 1938
- Public Health Service Act of 1944
- National Environmental Policy Act of 1969

Regulatory responsibilities:
- Title 21 Code of Federal Regulations
FDA Implementation of NEPA

Council on Environmental Quality

40 CFR, Part 1500 - 1508

1) Categorical Exclusions
2) Environmental Assessments
3) Environmental Impact Statements

FDA Regulations

NEPA regs -- 21 CFR Part 25
Categorical Exclusion

Classes of actions that individually or cumulatively do not significantly affect the quality of the human environment are ordinarily excluded from the requirement to prepare an EA or EIS.
Categorical Exclusions

- Action on original and abbreviated new human and animal drugs and biologics if there is no increase in use of the active moiety

- Approvals of original and abbreviated human drugs entry into aquatic environment < 1 PPB

- Action on a drugs and biologics for a naturally occurring substance if no significant change

- Investigations on new human and animal drug
Categorical Exclusions

Veterinary approvals for:

- non-food animals
- individually given anesthetics
- topicals & ophthalmics
- Rx drugs for terrestrial species

Extraordinary circumstances trump a claim of categorical exclusion.
Extraordinary circumstances

- At the expected level of exposure there is the potential for serious harm to the environment

- Adverse effect on species or the critical habitat of an endangered or threatened species
FDA Actions that may* need Environmental Assessment

Approval of:
- New Drug Application (NDA),
- Biologics License Application (BLA),
- New Animal Drug Application (NADA)
- Device Pre-Market Approval (PMA)

Action on:
- Investigational New Drug Application (IND)
- Investigational New Animal Drug Application (INAD)
- Investigational Device Exemption (IDE)

* Unless Excluded by 21 CFR 25.31
Agency’s Roles and Priorities

- Review categorically exclusions
- Review the EA submitted by the sponsor.
- Determine appropriate action:
  - Finding of No significant Impact (FONSI)
  - Environmental Impact Statement (EIS)
FDA Environmental Assessment

- Concise public document
- Sufficient evidence and analysis
  - environmental impact statement or
  - a finding of no significant impact.
- Aids an agency's compliance with NEPA
- Facilitates preparation of EIS
- Includes:
  - need for the proposal
  - alternatives
  - list of agencies and persons
- Identifies potential mitigations
Availability

Most actions are categorically excluded

- published in the Federal Register

Many actions have environmental assessments

- published in the Federal Register
- public display in our Document Management
- 113 Environmental Assessment for new animal drugs and feed additives
  on line at:
  (http://www.fda.gov/cvm/efoi/ea/ea.htm)
Current and Future Environmental Assessments

Risk = exposure to a chance of loss (or of losing something we value)

Risk = Hazard x Exposure
NAS Risk Assessment Paradigm (1983)

Risk Assessment

- Hazard Identification
- Dose-Response (effects) Assessment
- Exposure Assessment
- Risk Characterization

Risk Management
Ecological Risk Assessment

PROBLEM FORMULATION

ANALYSIS

Characterization of Exposure
Characterization of Ecological Effects

RISK CHARACTERIZATION

As Necessary: Acquire Data, Iterate Process,
Monitor Results

Communicating Results to the Risk Manager

Risk Management and Communicating Results to Interested Parties

Planning (Risk Assessor/Risk Manager/Interested Parties Dialogue)
EA Focus

- Ecosystem protection
- Laboratory studies on invertebrates, fish, plants at different trophic levels
- Measurement endpoints: mortality, immobilization, reproduction, growth, functional responses
- Biogeochemical cycling (nitrogen, carbon transformation)
Guidance

CDER guidance

*Environmental Assessment of Human Drug and Biologics Applications (July 1998)*
http://www.fda.gov/cder/guidance/index.htm

CVM guidance

*Environmental Impact Assessment for Veterinary Medicinal Products*

Phase I (Sept. 1998)
(http://www.fda.gov/cvm/guidance/guide89.PDF)
VICH Veterinary Drug

Phase II (pending final FDA adoption)
Human Tiered Approach

Figure 1
Tiered Approach to Fate and Effects Testing

Determine environments of Potential Concern
Atmospheric, Aquatic and/or Terrestrial

Investigate Depletion Mechanism(s)
rapid
complete

No rapid, complete depletion mechanism

Microbial Inhibition Test

Log Kow ≥ 3.5 CONSIDER initiating chronic toxicity testing

Log Kow < 3.5 or Log Kow ≥ 3.5 with justification

TIER 1
Acute Toxicity
1 species
LC or EC 50 ≤ 1000 MEEC

TIER 2
Acute Toxicity Base Set
Aquatic &/or Terrestrial
LC or EC 50 ≤ 100 MEEC

TIER 3
Chronic Toxicity
Aquatic &/or Terrestrial
LC or EC 50 ≤ 10 & No observed Effects at MEEC

Consult CDER

Note: MEEC = EEC or EIC whichever is greater
Veterinary Phase I Guidance

- legal and exposure criteria
- exempt from full risk analysis
- extensive *in vivo* metabolism
- aquatic introduction concentration < 1 μg/L
- terrestrial introduction concentration < 100 μg/Kg
Veterinary Phase II

Risk-quotient method  = PEC : PNEC.

- Predicted environmental concentration (PEC)
- Predicted no effect concentration (PNEC)
- Assessment Factor (AF)
- Three Tiers (A,B,C) as needed
Veterinary Scenarios Phase II Guideline

Intensively reared animals

Storage tank

pasture animals

aquaculture
Assessment Factors

- Numerical factor that is applied to the endpoint value of an effects study to derive a predicted no-effect concentration (PNEC)

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Interspecies</td>
<td>X10</td>
</tr>
<tr>
<td>Laboratory to Field</td>
<td>X10</td>
</tr>
<tr>
<td>Acute to Chronic</td>
<td>X10</td>
</tr>
</tbody>
</table>
Base Set Data Requirements

**Physical-chemical studies**
- Water Solubility
- Dissociation Constant
- UV-Visible Absorption Spectrum
- Melting Temperature
- Vapour Pressure
- Octanol/Water Partition

**Environmental fate studies**
- Soil adsorption/desorption
- Degradation in soil
- Degradation in aquatic systems
- Photolysis (optional)
- Hydrolysis (optional)

**Aquatic effect studies**
- Algae
- Daphnia
- Fish

**Terrestrial effect studies**
- Micro-organisms
- Terrestrial plants
- Earthworm
# Tier A Assessment

<table>
<thead>
<tr>
<th>Environment</th>
<th>Endpoint</th>
<th>AF</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Surface water</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• algae (96 h)</td>
<td>EC50</td>
<td>100</td>
</tr>
<tr>
<td>• invertebrate (48 h)</td>
<td>EC50</td>
<td>1000</td>
</tr>
<tr>
<td>• fish (96 h)</td>
<td>LC50</td>
<td>1000</td>
</tr>
<tr>
<td><strong>Soil</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• earthworm (chronic)</td>
<td>NOEC</td>
<td>10</td>
</tr>
<tr>
<td>• higher plants (3 species)</td>
<td>EC50</td>
<td>100</td>
</tr>
<tr>
<td>• micro-organisms (28 days)</td>
<td>&lt; 25% of control</td>
<td></td>
</tr>
<tr>
<td><strong>Dung (pasture animals)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• dung fly</td>
<td>EC50</td>
<td>100</td>
</tr>
<tr>
<td>• dung beetle</td>
<td>EC50</td>
<td>100</td>
</tr>
</tbody>
</table>
TIER B Assessment

<table>
<thead>
<tr>
<th>Surface water</th>
<th>Endpoint</th>
<th>AF</th>
</tr>
</thead>
<tbody>
<tr>
<td>algae (96 h)</td>
<td>NOEC</td>
<td>10</td>
</tr>
<tr>
<td>invertebrate (21 d)</td>
<td>NOEC</td>
<td>10</td>
</tr>
<tr>
<td>fish (28 d)</td>
<td>NOEC</td>
<td>10</td>
</tr>
<tr>
<td>sediment species (varies)</td>
<td>NOEC</td>
<td>10</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Soil</th>
<th>Endpoint</th>
</tr>
</thead>
<tbody>
<tr>
<td>earthworm</td>
<td>no recommendation</td>
</tr>
<tr>
<td>higher plants (more species)</td>
<td>NOEC</td>
</tr>
<tr>
<td>micro-organisms (100 days)</td>
<td>&lt; 25% of control</td>
</tr>
</tbody>
</table>

Bioaccumulation

- BCF > 1000 l/kg ⇒ investigate secondary poisoning
TIER C Assessment

Refined Risk Analysis
• Specialized environmental fate modeling
• Probabilistic exposure analyses

Specialized Laboratory and/or Field Testing
• Pulsed exposure studies
• Microcosm and mesocosm studies
• In-stream studies

Risk Management
• Use restrictions
• Mandatory treatment requirements
• Effluent discharge limits
On-going Activities

On-going collaborations:

- With the Office of Clean Water/EPA on animal drugs in effluents from aquaculture facilities
- With the Joint Subcommittee on Aquaculture on environmental impact of animal drugs used in aquaculture
- With USGS Toxic program and EPA Field offices on pharmaceuticals in the environment
On-going Activities

- Veterinary International Conference on Harmonisation
- Conferring with pharmaceutical manufacturers on improved methods to estimate environmental exposure levels
- Monitoring literature reports associated with PPCPs in the environment
Planned Activities

- Organizing workshop with Society of Environmental Toxicology & Chemistry on veterinary drugs in the environment
- Assess the value of providing guidance on disposal of unused drugs
Science Needs

- Data on background levels from natural sources (including humans)
- Data on levels of mimics from industrial sources
- Data on minimum effect levels
  - Pharmaceuticals
- Comparison of predicted and actual levels of pharmaceuticals
Science Needs

Specific questions:

- Effects of ‘sunscreens’ on aquatic environment
- Effects of triclosan on aquatic environment
Thank You

Charles E. Eirkson III

FDA, CVM
Environmental Safety Team, HFV-103
7500 Standish Place
Rockville MD 20855
301-827-6653
ceirkson@cvm.fda.gov

CVM Web site
http://www.fda.gov/cvm/